eFFECTOR Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28202V2079
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

329

Shareholding (Mar 2024)

FII

8.32%

Held by 7 FIIs

DII

71.54%

Held by 3 DIIs

Promoter

17.00%

Is eFFECTOR Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, eFFECTOR Therapeutics, Inc. is rated as attractive due to its undervaluation, with key financial ratios indicating a solid position compared to peers like Amgen and Gilead Sciences, and it has recently outperformed the Sensex.

As of 5 October 2023, eFFECTOR Therapeutics, Inc. has moved from a fair to an attractive rating. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, which indicate a solid financial position relative to its earnings and assets.<BR><BR>In comparison to its peers, eFFECTOR Therapeutics is more favorably positioned than companies like Amgen, which has a price-to-earnings ratio of 15.2, and Gilead Sciences, with a price-to-book ratio of 3.0. This suggests that eFFECTOR is trading at a discount relative to its industry counterparts. Additionally, recent stock performance has shown resilience, outperforming the Sensex, further supporting the notion of its undervaluation.

Read More

Is eFFECTOR Therapeutics, Inc. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is insufficient technical data for eFFECTOR Therapeutics, Inc. to determine a bullish or bearish outlook.

As of 1 November 2023, the technical data for eFFECTOR Therapeutics, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-6.41

stock-summary
Return on Equity

-3,463.60%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2024)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
100.0%
0%
100.0%
1 Year
0%
0%
0.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-99.95%
0%
-99.95%
4 Years
-100.0%
0%
-100.0%
5 Years
0%
0%
0.0%

eFFECTOR Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-275.79%
EBIT to Interest (avg)
-16.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-6.41
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
40.83%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.00
EV to EBIT
0.20
EV to EBITDA
0.20
EV to Capital Employed
1.15
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
585.34%
ROE (Latest)
-3463.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (3.14%)

Foreign Institutions

Held by 7 Foreign Institutions (8.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2024 is 3.30% vs -9.64% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.40",
          "val2": "-8.60",
          "chgp": "2.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.80",
          "chgp": "-12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.80",
          "val2": "-9.10",
          "chgp": "3.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -100.00% vs 0.00% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -57.71% vs -243.67% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "3.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.70",
          "val2": "-32.40",
          "chgp": "-4.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.90",
          "val2": "2.30",
          "chgp": "26.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "12.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.80",
          "val2": "-22.70",
          "chgp": "-57.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-9,119.90%",
          "chgp": "911.99%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQstock-summary
Mar'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.40
-8.60
2.33%
Interest
0.70
0.80
-12.50%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.80
-9.10
3.30%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

QoQ Growth in quarter ended Mar 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2024 is 3.30% vs -9.64% in Dec 2023

Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
3.60
-100.00%
Operating Profit (PBDIT) excl Other Income
-33.70
-32.40
-4.01%
Interest
2.90
2.30
26.09%
Exceptional Items
0.00
12.10
-100.00%
Consolidate Net Profit
-35.80
-22.70
-57.71%
Operating Profit Margin (Excl OI)
0.00%
-9,119.90%
911.99%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -100.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -57.71% vs -243.67% in Dec 2022

stock-summaryCompany CV
About eFFECTOR Therapeutics, Inc. stock-summary
stock-summary
eFFECTOR Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available